You are very welcome. Good luck.
Thank you for your response.
The fainting you describe is worrisome. The progression of urticaria to anaphylaxis is theoretically possible but I could find no reports of such. However, there is a wide spectrum of severity of all types of urticaria and it is possible that one or more of the features of anaphylaxis could accompany urticaria, in the absence of classical anaphylaxis.
Observation and measurement of pulse and blood pressure by a medical professional might help by providing objective information regarding the altered physiology associated with your fainting.
The avoidance of exposure to sunlight is the most reliable preventive measure. Note that some garment materials may fail to completely block the sun’s rays. Some Antihistamines in use have topical preparations to absorb or reflect light. Some agents contain titanium oxide, zinc oxide, or both. More recently, are reports of intravenous immunoglobulin use for this condition (see example, below)
Good luck
Title Solar urticaria treated with intravenous immunoglobulins.
SourceJournal of the American Academy of Dermatology. 65(2):336-40, 2011 Aug.
Abstract
BACKGROUND: Solar urticaria (SU) is a rare idiopathic photodermatosis induced immediately after sun exposure. This disorder may considerably restrict normal daily life and management is extremely difficult when treatment with oral H1 antihistamines and sun avoidance are ineffective.
OBJECTIVE: We sought to report the effectiveness of intravenous immunoglobulins (IVIG) in severe SU.
METHODS: We performed a retrospective multicentric study via the mailing of a questionnaire to the French photodermatology units to analyze all cases of patients with SU who were treated with IVIG.
RESULTS: Seven patients (5 women) with a mean age of 40 years (range 32-55 years) and a mean disease duration of 5 years (range 2-10 years) received IVIG. The administration schedule differed from one patient to another: 1.4 to 2.5 g/kg were infused over 2 to 5 days. Five of 7 patients obtained a complete remission. The number of courses necessary to obtain clinical remission varied from 1 to 3 courses. Complete remission was maintained during 4 to more than 12 months but antihistamines were still required. In one case, psoralen plus ultraviolet A photochemotherapy was administered.
LIMITATIONS: Retrospective study design, limited number of patients, and variations in the IVIG administration schedule could limit the interpretation of the results.
CONCLUSION: Our case series suggests a beneficial effect of IVIG in severe SU but additional prospective trials including a larger number of patients are needed to demonstrate the effectiveness of IVIG and to specify the optimal modalities of their administration in this disease.